Nordman

Quick links to important sections

Nordman

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nordman

Quick Facts

Property Description
Active Ingredient Dequalinium Chloride (INN)
Pharmacological Class Local Antiseptic / Anti-Infective Agent
Primary Forms Vaginal tablet, Lozenge, Topical solutions
Origin Synthetic (Quaternary ammonium compound)
General Purpose Microbial control of Local infections

What Type of Medicine is Nordman (Dequalinium Chloride)?

Nordman is a pharmaceutical product defined by its sole Active ingredient, Dequalinium Chloride. It is officially classified within the high-level Pharmacological class of local Antiseptic and Anti-Infective Agents, a classification supported by its inclusion in various international treatment guidelines. Chemically, Dequalinium Chloride is a Synthetic bis-quaternary ammonium compound, a specialized structure that allows it to exert its therapeutic effect primarily on the surface or local area of application. This mechanism minimizes its absorption into the body, ensuring its action is concentrated where it is needed most. Dequalinium Chloride is clinically recognized for its reliable action against a wide range of common pathogens, confirming its utility in localized therapy.

Composition, Forms, and General Therapeutic Purpose

The medicine typically functions as a Single active component product, relying on Dequalinium Chloride delivered via a neutral carrier. Nordman is commonly known for its formulation as a Vaginal tablet, which distinguishes it as a targeted delivery system for gynecological applications, though the active ingredient is also available in Lozenge and solution preparations. It is designed for Topical or localized application. The general Therapeutic use of Dequalinium Chloride is to achieve microbial control by rapidly eliminating the Bacterial and Fungal organisms that cause localized infections. This compound offers a safe and efficient option for managing infections by providing a potent local anti-infective effect. This action helps prevent the infection from progressing and supports the rapid resolution of local symptoms, such as discomfort associated with minor microbial overgrowth.

What side effects are possible with Nordman?

Possible Side Effects and Safety Information

The safety profile for Nordman (Dequalinium Chloride) is primarily characterized by localized reactions at the application site, as documented in official regulatory sources like the Summary of Product Characteristics (SmPC).

Classification Element Regulatory Description
Common Adverse Reactions Affecting 1 to 10 users in 100, these are often localized and include vaginal discharge, vulvovaginal pruritus (itching), and vulvovaginal burning sensation.
Uncommon Adverse Reactions Affecting 1 to 10 users in 1,000, these include systemic effects like headache and nausea, as well as local effects such as vaginal haemorrhage.
Frequency Not Known Events Events reported primarily post-marketing include allergic reactions (such as urticaria, rash, or oedema) and local irritation reactions like bleeding surface defects or erosions of the vaginal epithelium.

System-Organ Classes and Restrictions

Adverse reactions are officially grouped by the body system affected, primarily categorized under Reproductive system and breast disorders and General disorders and administration site conditions.

Contraindications (Safety Restrictions) explicitly listed in the regulatory documents include known hypersensitivity to Dequalinium Chloride or any excipients, and existing ulceration of the vaginal epithelium or portio vaginalis uteri.

Population-Specific Safety Statements

  • Pregnancy and Lactation: Use is generally permitted. However, official labeling advises that the vaginal tablet should not be used within 12 hours prior to delivery to minimize newborn exposure to the active substance.
  • Pediatric Use: The vaginal form is contraindicated in girls who have not reached sexual maturity (first menstruation), as safety and efficacy data are not sufficient for this population.

Overdose and Emergency Response

Official Regulatory Information: Overdose and Emergency Actions

The official regulatory profile for Nordman (Dequalinium Chloride) defines the overdose risk based on local effects and accidental ingestion, consistent with its classification as a local antiseptic. Regulatory documentation does not report specific severe or life-threatening systemic outcomes for the sole active ingredient.

Documented Overdose Presentations

Exposure Route Documented Manifestations
Local Overexposure Vaginal ulcerations resulting from the use of a higher daily dose or a treatment duration exceeding the recommended course for the vaginal tablet.
Accidental Ingestion Gastrointestinal discomfort is the anticipated oral overdosage effect. Additionally, reported cases have included nausea, abdominal pain, vomiting, and diarrhea.

When to Seek Urgent Medical Help

Regulators explicitly mandate that individuals must seek immediate medical attention if any documented signs of overexposure are experienced. This instruction applies when local tissue damage, such as ulcerations, or persistent gastrointestinal adverse events develop.

Official Supportive Measures

Regulatory documentation confirms that no specific antidote is known for Dequalinium Chloride overdose, and management is primarily supportive. For local overdose of the vaginal form that results in adverse events, the official procedure of vaginal lavage is described as a potential supportive measure. Treatment for symptoms related to accidental ingestion is strictly symptomatic. No specific hospital monitoring or observation requirements are explicitly mandated in the official overdose sections.

Therapeutic Uses of Nordman

What Nordman Treats: Main Uses and Benefits

Nordman is commonly used to manage symptom clusters related to local microbial overgrowth, particularly in conditions like Bacterial Vaginosis (BV) and is also applicable for acute pharyngeal discomfort. Its anti-infective use in the gynecological domain is considered relevant in contexts involving inflammatory or irritative processes, offering a non-antibiotic approach for local relief.

This medicine helps address the distressing symptomatic patterns of vaginal infections, including abnormal discharge, offensive odor, and associated itching or burning sensation. In the oral domain, it is applied for local soreness and pain linked to pharyngitis or tonsillitis. This supportive relief contributes to easing the overall symptom burden and supports general well-being during symptomatic phases.

Quick Fact: Supportive Management of Local Discomfort
Symptoms the Medicine Helps Address: Vaginal discharge, odor, itching, and sore throat pain.
Typical Context: Conditions involving local microbial overgrowth or acute inflammatory states of the throat.
Patient Benefit: Contributes to improved comfort and eases the overall symptom burden during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nordman?

Eligibility for Nordman (Dequalinium Chloride) is strictly defined by regulatory guidelines based on population health status and age. The medicine is primarily intended for adult women between 18 and 55 years of age.

Absolute Contraindications

Use of this medicine is absolutely prohibited (contraindicated) for specific groups, including:

  • Patients with hypersensitivity to Dequalinium Chloride or any of the inactive ingredients.
  • Premenarchal girls (those who have not reached sexual maturity).
  • Patients with ulceration of the vaginal epithelium or cervix.

Age and Conditional Restrictions

Use is not established in women under 18 years and over 55 years due to a lack of sufficient efficacy and safety data in these populations.

Eligibility Status Applicable Population
Permitted Lactating women; Pregnancy (Second and Third trimesters).
Caution Advised Pregnancy (First trimester).
Prohibited Timing Within 12 hours before birth to minimize newborn exposure.

No specific restrictions concerning use in patients with renal or hepatic impairment are documented, consistent with the medicine's local action and negligible systemic absorption.

What should I know about interactions with other medicines?

Local Interaction Profile

Nordman (Dequalinium Chloride) is a locally acting anti-infective agent. Due to its minimal systemic absorption into the bloodstream, interactions with other systemic medicinal products are not expected and have not been established in regulatory documents. This minimal systemic exposure also confirms that no interactions affecting drug metabolism (such as via CYP enzymes) or systemic interactions with alcohol or food are officially documented.

Documented Local Incompatibilities

The official interaction profile focuses on local restrictions related to co-administration.

Interaction Type Interacting Substance/Product Regulatory Restriction
Pharmacodynamic Antagonism Anionic substances (soaps, detergents, spermicides, vaginal washes) Co-administration is restricted as these substances may formally reduce the antimicrobial activity of the active ingredient.
Physical Incompatibility Non-latex condoms and diaphragms The product may reduce the effectiveness of these devices. Alternative contraception must be used, and a 12-hour separation rule applies following treatment.

These restrictions also apply to the concomitant use of other intravaginal products, including natural health, herbal, or cosmetic preparations. The entire interaction structure is defined by the need to prevent local antagonism and device interference rather than systemic risk.

Mechanism of Action

How Nordman Works

Nordman's action is defined by a multi-targeted, rapid, and localized anti-infective mechanism. The core of its pharmacological activity is focused on the immediate physical and metabolic disruption of susceptible microbial cells, which results in localized microbial cellular death.


Direct Disruption of Microbial Cell Integrity

As a cationic bis-quaternary ammonium compound, the molecule targets the negatively charged cell membrane of bacteria and fungi, causing a strong electrostatic interaction. This interaction rapidly disrupts the membrane structure, leading to critical leakage of vital intracellular components and initiating cellular collapse (lysis).


Inhibition of Pathogen Metabolism and Replication

Simultaneously, the agent acts as an inhibitor against essential microbial metabolic enzymes, including those in the respiratory chain, thereby halting ATP synthesis and energy generation. This multi-hit cascade—combining physical disruption with metabolic paralysis—results in a rapid fungicidal and bactericidal physiological consequence confined to the local area.

Dosage and Administration Information

How to Use Nordman

Nordman (Dequalinium Chloride) is an anti-infective agent used exclusively by the intravaginal route as a 10 mg vaginal tablet. Adherence to the prescribed course duration and administration technique is central to its proper use.


Standard Regimen and Duration

The standard adult dosing regimen requires the insertion of one vaginal tablet daily, with treatment lasting for a fixed course of six consecutive days. This once-daily frequency is scheduled for the evenings before retiring. The full six-day course must be completed, even if symptoms begin to resolve early, as a shorter duration of treatment is associated with a risk of relapse.


Administration Conditions and Constraints

The tablet must be inserted deeply into the vagina. To facilitate proper dissolution, particularly if the vagina is very dry, the tablet can be moistened with a drop of water prior to insertion. The optimal position for administration is reclining with the legs slightly bent.

Treatment must be interrupted during menstruation and then immediately resumed afterward to complete the prescribed six-day regimen. Furthermore, the use of vaginal douches, spermicides, or soaps should be avoided during treatment. While the use of latex condoms is not restricted, non-latex condoms or other intravaginal devices should be avoided for at least 12 hours following the administration of the tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nordman

The clinical evaluation of Nordman (Dequalinium Chloride) focuses on the research base for local antiseptic use in two main areas: localized vaginal infections and acute mouth/throat discomfort. The evidence base includes multiple study types, and the findings help contextualize how patients reported their experience during defined observation periods.


Evidence for Use in Localized Vaginal Infections

Research exploring the use of the vaginal tablet formulation has primarily involved Randomized Controlled Trials (RCTs). These studies were used to evaluate outcomes related to symptom patterns in comparison with established standard treatments, such as certain antibiotics or antifungals. The research examined several outcomes, including the return of normal vaginal pH and flora (often called microscopic cure), and measurements of changes in symptoms related to physical discomfort, such as abnormal discharge or odor (clinical cure).

Studies reported measurements of short-term clinical and microscopic outcomes that were within the same range as the measurements observed in patients receiving comparator standard treatments. These findings help contextualize how patients reported their experience during the study period. Trials reported on the incidence of adverse events and discontinued treatment during the study period.

Evidence for Use in Acute Localized Mouth and Throat Discomfort

Nordman lozenges was studied for use in patients experiencing conditions associated with acute or disruptive episodes in the mouth and throat. Studies monitored outcomes related to physical discomfort, specifically the intensity of the sore throat and changes in localized signs, such as inflammation or redness. Studies described that the local antiseptic did not influence systemic symptoms or signs caused by certain specific pathogenic bacteria, and the observations focused primarily on localized changes in symptoms.

What is Still Uncertain and Research Gaps

Research highlights several limitations. There is limited information for long-term outcomes regarding the sustained changes in infections, as follow-up durations were limited in many primary trials. Evidence quality varies across studies, and the data for specific populations, like pregnant women, remain insufficient. Comparative evidence is also lacking against newer therapeutic options or across a wider global patient population. Research provides context but not individual predictions, and studies help show what has been observed so far under the specific conditions under which they were conducted.

Key Studies & References

  1. Assessment of Dequalinium Chloride vs Clindamycin for the Treatment of Bacterial Vaginosis (Phase III Non-Inferiority Study)
  2. The DEVA trial: protocol for a randomised controlled trial of dequalinium chloride versus usual care antibiotics for the treatment of bacterial vaginosis (DEVA)

Frequently Asked Questions (FAQ)

Common questions about Nordman (FAQ)


Q: How quickly does Nordman start working after you take it?

Regulatory data indicates that the bactericidal (bacteria-killing) effect of the active ingredient typically begins within 30 to 60 minutes of application. Symptom relief from discharge and inflammation generally begins to occur within the first one to three days of starting the treatment course.


Q: What happens if I stop taking Nordman suddenly?

The official product information emphasizes the necessity of completing the full six-day treatment course as prescribed. Stopping the medication before the full course is finished, even if symptoms have improved, is associated with a risk of the infection returning (relapse).


Q: Is it normal to feel a bit tired when first starting Nordman?

Tiredness or fatigue is not specifically listed as a common or uncommon side effect in the official regulatory documents. However, these documents do report that headache is an uncommon side effect, affecting a small percentage of users (1 to 10 in 1,000).


Q: Do most people experience side effects with Nordman?

Side effects are generally localized to the application area. The most common local effects, such as vaginal discharge, itching, or a burning sensation, are reported as 'Common,' meaning they affect approximately 1 to 10 users in every 100.


Q: Can Nordman be taken with common pain relievers like Tylenol or Advil?

Regulatory documents state that Nordman is a locally acting medication with minimal absorption into the bloodstream. For this reason, no interactions with systemic medicinal products, such as orally taken pain relievers (e.g., acetaminophen or ibuprofen), are expected or officially documented.


Q: Are there any long-term studies available on Nordman?

Official research summaries note that there is limited information available concerning the long-term outcomes of using Nordman. The follow-up period in most primary clinical trials has been short, focusing mainly on short-term relief and cure.


Q: What is the maximum amount of time someone can safely take Nordman?

The standard therapeutic regimen for Nordman is a fixed, short course of six consecutive days. The regulatory information does not provide specific safety or efficacy data for using the medication beyond this duration or for immediate re-treatment following a non-response.


Q: What is the active ingredient in Nordman?

The sole active substance in Nordman is Dequalinium Chloride. This is the component responsible for the medication’s local anti-infective effect.


Q: Is it necessary to take Nordman with food, or can I take it on an empty stomach?

Nordman is designed for local vaginal use, and its active ingredient has negligible absorption into the body. Therefore, official product information confirms that no systemic interactions with food are expected or documented.


Q: How should Nordman be stored (e.g., room temperature, refrigerated)?

The medication should be stored under conditions that maintain its quality. This generally means the product should not be stored above 30°C and must be kept protected from moisture and freezing.


Q: Is Nordman an antibiotic or an antiviral?

Nordman is classified as a local anti-infective and antiseptic agent rather than a systemic antibiotic or antiviral. It demonstrates broad bactericidal (kills bacteria) and fungicidal (kills fungi) activity against the organisms that cause localized infections.


Q: Is it safe to drink alcohol in moderation while taking Nordman?

Due to the medicine's local action and negligible absorption into the bloodstream, systemic interactions with alcohol are not expected and have not been officially documented.


Q: Does Nordman affect mental clarity or ability to drive?

Based on its local action and minimal systemic absorption, the official product information indicates the medicine is not expected to affect mental clarity or the ability to drive or operate machinery.


Q: Can Nordman affect sleep patterns (insomnia or drowsiness)?

Insomnia or drowsiness is not explicitly listed as a known or uncommon side effect in the regulatory safety information. However, headache is reported as an uncommon side effect.


Q: Does Nordman come in different strengths or forms (tablet, liquid, etc.)?

The official gynecological formulation is the 10 mg vaginal tablet. While the active ingredient, Dequalinium Chloride, is available in other topical forms (such as lozenges) for different uses, the approved preparation for this specific indication is the vaginal tablet.


Q: Does caffeine interact with Nordman?

Because the product acts locally with minimal systemic absorption, official regulatory documents state that no systemic interactions with food or beverages, including caffeine, are expected.


Q: What is the typical timeframe for a Nordman prescription?

The required treatment course for Nordman is defined as a short duration of six consecutive days.


Q: Does taking Nordman require regular blood tests or monitoring?

Since the product acts locally and has negligible systemic absorption, regulatory documents do not specify a need for regular blood tests or other forms of systemic monitoring.


Q: Is Nordman used to treat acute issues or long-term conditions?

Nordman is used for the acute treatment of localized infections and is administered over a defined, short course of six days.


Q: Are there any known allergic reactions to Nordman I should be aware of?

Official information indicates that allergic reactions, such as rash, swelling, or hives, have been reported post-marketing. Known hypersensitivity to the active ingredient or any excipients is an absolute contraindication for use.

How should Nordman be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents establish mandatory storage and handling conditions to ensure a drug product’s identity, strength, quality, and purity (ISQP) are maintained until the expiration date. These requirements govern how the medicine must be protected and ultimately discarded.

Storage Component Official Requirement Basis
Temperature and Environment Must be stored under conditions that maintain ISQP; specific ranges (e.g., “Store below 30°C”) prevent deterioration from temperature extremes.
Protection Packaging must protect the drug from external factors like moisture and light. Handling instructions prohibit exposure to conditions that could compromise product quality, such as freezing.
Child Safety Instructions are required to prevent accidental exposure by children or pets, particularly for potent or high-risk forms.
Disposal Unused or expired medicine must be disposed of according to local regulatory authority guidance to prevent environmental contamination and accidental harm.

Disposal must align with official protocols for pharmaceutical waste, often requiring return programs or specific household disposal methods. Proper storage and disposal are strictly defined by regulatory standards (e.g., FDA CGMP, EMA guidelines) to ensure the product remains safe and effective.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nordman found in:

A-Z Index: